Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (521-530 of 564) with videos related to

Pageof 57
Sort By:
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
The Lancet. Oncology|March 15, 2021
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.
Critical Reviews in Oncology/Hematology|June 21, 2015
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of OncologyRiccardo Valdagni, Hendrik Van Poppel, Michael Aitchison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerC J Pezaro, A Omlin, K Mastris, et al.
The New England Journal of Medicine|September 18, 2020
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaThomas Powles, Se Hoon Park, Eric Voog, et al.
Communications Medicine|January 12, 2026
Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohortMajd Al Assaad, Kevin Hadi, Max F Levine, et al.
Pageof 57

Showing results (521-530 of 564) with videos related to

Sort By:
Pageof 57
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
The Lancet. Oncology|March 15, 2021
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.
Critical Reviews in Oncology/Hematology|June 21, 2015
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of OncologyRiccardo Valdagni, Hendrik Van Poppel, Michael Aitchison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerC J Pezaro, A Omlin, K Mastris, et al.
The New England Journal of Medicine|September 18, 2020
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaThomas Powles, Se Hoon Park, Eric Voog, et al.
Communications Medicine|January 12, 2026
Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohortMajd Al Assaad, Kevin Hadi, Max F Levine, et al.
Pageof 57